Virbac SA (VIRP) AI Stock Analysis

• Market Cap: €2.71B
• Dividend Yield: 0.41%
• Average Volume (3M): 4.22K
• Price to Earnings (P/E): 18.7
• Beta (1Y): 0.65
• Revenue Growth: 12.07%
• EPS Growth: 20.48%
• Country: FR
• Employees: 6,365
• Sector: Healthcare
• Sector Strength: 44
• Industry: Drug Manufacturers - General
• EPS (TTM): 17.35
• Shares Outstanding: 8,390,660
• 10 Day Avg. Volume: 4,278
• 30 Day Avg. Volume: 4,220
• PEG Ratio: 2.03
• Price to Book (P/B): 2.29
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 42.42
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €375.33
• Price Target Upside: 15.84% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 75 Outperform
• Price Target: €359.00 ▲(10.80%Upside)

Virbac SA's strong financial performance is a key driver of its overall score, reflecting solid profitability and growth with minimal leverage. Technical analysis supports the stock's positive momentum, while its valuation remains reasonable. The lack of earnings call data and corporate events did not impact the score.

Positive Factors

Regional Growth

Europe and Latin America are experiencing robust growth rates of around 8%, contributing positively to Virbac's overall performance.

Sales Performance

Virbac's first-quarter sales figures met expectations with organic growth of 4.9%.

Negative Factors

Earnings Growth

There is a likelihood of a slowdown in earnings growth in the first half of the year due to an unfavorable base effect.

Regional Decline

Australia is experiencing a significant decline with a 15% decrease, negatively impacting Virbac's sales in the Pacifique region.

Virbac SA Business Overview & Revenue Model

Company Description

Virbac SA is a global animal health company that develops, manufactures, and distributes a comprehensive range of products and services for veterinarians, livestock farmers, and pet owners. The company's offerings include vaccines, pharmaceuticals, and nutritional products for both companion animals and livestock, catering to the health and well-being of animals across various species.

How the Company Makes Money

Virbac SA generates revenue through the sale of its diverse portfolio of animal health products, catering to both companion animals and livestock. Key revenue streams include veterinary pharmaceuticals, vaccines, and nutritional products. The company focuses on developing innovative solutions to meet the evolving needs of the animal health industry, leveraging research and development to create advanced products. Additionally, Virbac engages in strategic partnerships and collaborations with veterinary clinics, distributors, and research institutions, which help in expanding market reach and enhancing product offerings. These partnerships, along with a robust distribution network, play a significant role in driving the company's earnings.

Virbac SA Financial Statement Overview

Summary

Virbac SA demonstrates a strong financial profile with consistent revenue growth, robust profitability margins, and minimal leverage. The company effectively manages costs and utilizes shareholder equity efficiently, while maintaining solid cash flow generation.

Income Statement

Virbac SA demonstrates a strong income statement with consistent revenue growth over the years. Gross Profit Margin in 2024 is approximately 67.4%, reflecting efficient cost management. Net Profit Margin stands at about 10.4%, indicating a solid profitability level. EBIT Margin of 15.5% and EBITDA Margin of 20.4% showcase robust operational efficiency. Revenue grew by approximately 12.1% from 2023 to 2024, indicating a healthy upward trajectory. Overall, the company shows strong profitability and growth, with a continuous positive trend.

Balance Sheet

The balance sheet of Virbac SA is stable with a low Debt-to-Equity Ratio of 0.04, indicating minimal leverage and financial risk. Return on Equity (ROE) is approximately 13.9%, showcasing effective utilization of shareholder equity to generate profits. The Equity Ratio of 56.4% suggests a solid capital structure with a significant portion of assets financed by equity. These metrics indicate financial stability and a well-managed balance sheet with minimal debt risk.

Cash Flow

Virbac SA's cash flow statement shows solid cash generation capabilities with a Free Cash Flow Growth Rate of approximately 128.5% from 2023 to 2024. The Operating Cash Flow to Net Income Ratio is about 1.4, indicating good cash conversion. Free Cash Flow to Net Income Ratio stands at 0.93, reflecting efficient management of capital expenses. The company exhibits strong cash flow management, though a higher free cash flow conversion ratio would further enhance its cash flow position.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
1.40B	1.25B	1.22B	1.06B	934.20M
	Gross Profit
937.60M	422.67M	427.27M	378.38M	290.41M
	EBIT
217.07M	184.88M	173.33M	160.10M	112.04M
	EBITDA
284.85M	230.65M	215.55M	199.46M	231.67M
	Net Income Common Stockholders
145.29M	121.30M	121.97M	113.16M	136.04M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
149.63M	175.91M	177.38M	172.79M	181.89M
	Total Assets
1.85B	1.46B	1.36B	1.22B	1.11B
	Total Debt
307.01M	120.11M	91.49M	95.37M	116.22M
	Net Debt
157.38M	-55.80M	-85.89M	-77.41M	-65.67M
	Total Liabilities
805.12M	545.81M	521.17M	498.84M	454.28M
	Stockholders Equity
1.04B	900.30M	839.33M	724.93M	620.97M
Cash Flow		Free Cash Flow
134.97M	59.06M	45.41M	79.13M	81.23M
	Operating Cash Flow
204.22M	118.64M	98.98M	126.29M	110.22M
	Investing Cash Flow
-428.69M	-121.87M	-54.83M	-106.22M	339.52M
	Financing Cash Flow
138.59M	-2.56M	-34.76M	-33.07M	-341.19M

Virbac SA Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 324.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:VIRP, the sentiment is Neutral. The current price of 324 is above the 20-day moving average (MA) of 320.48, above the 50-day MA of 308.87, and below the 200-day MA of 326.98, indicating a neutral trend. The MACD of 4.80 indicates Positive momentum. The RSI at 50.82 is Neutral, neither overbought nor oversold. The STOCH value of 15.68 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FR:VIRP.

Virbac SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SAN	76 Outperform	$106.82B	19.71	7.34%	4.47%	-4.62%	2.88%
VIRP	75 Outperform	€2.71B	18.67	14.95%	0.41%	12.07%	20.48%
VETO	73 Outperform	€869.22M	14.77	10.64%	1.20%	1.88%	5.79%
IPN	68 Neutral	€8.69B	25.15	8.89%	1.14%	8.73%	-46.34%
BOI	62 Neutral	€402.05M	35.15	2.94%	5.26%	-1.15%	-68.36%
Sector *	54 Neutral	$5.38B	3.40	-45.06%	3.28%	16.75%	-0.02%
MEDCL	37 Underperform	€529.10M	―		―	-1.66%	-6.31%